SG11201608299TA - Compounds and compositions as toll-like receptor 7 agonists - Google Patents
Compounds and compositions as toll-like receptor 7 agonistsInfo
- Publication number
- SG11201608299TA SG11201608299TA SG11201608299TA SG11201608299TA SG11201608299TA SG 11201608299T A SG11201608299T A SG 11201608299TA SG 11201608299T A SG11201608299T A SG 11201608299TA SG 11201608299T A SG11201608299T A SG 11201608299TA SG 11201608299T A SG11201608299T A SG 11201608299TA
- Authority
- SG
- Singapore
- Prior art keywords
- toll
- agonists
- receptor
- compositions
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987314P | 2014-05-01 | 2014-05-01 | |
| PCT/US2015/028285 WO2015168279A1 (en) | 2014-05-01 | 2015-04-29 | Compounds and compositions as toll-like receptor 7 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201608299TA true SG11201608299TA (en) | 2016-11-29 |
Family
ID=53264739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201608299TA SG11201608299TA (en) | 2014-05-01 | 2015-04-29 | Compounds and compositions as toll-like receptor 7 agonists |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US9944649B2 (sr) |
| EP (1) | EP3137468B1 (sr) |
| JP (1) | JP6541689B2 (sr) |
| KR (1) | KR20160144399A (sr) |
| CN (1) | CN106459058B (sr) |
| AU (1) | AU2015253225B2 (sr) |
| BR (1) | BR112016025048A2 (sr) |
| CA (1) | CA2945504A1 (sr) |
| EA (1) | EA032487B1 (sr) |
| ES (1) | ES2908150T3 (sr) |
| IL (1) | IL248311B (sr) |
| MX (1) | MX380777B (sr) |
| NZ (1) | NZ724878A (sr) |
| SG (1) | SG11201608299TA (sr) |
| WO (1) | WO2015168279A1 (sr) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3137470T3 (pl) | 2014-05-01 | 2021-10-11 | Novartis Ag | Zwiฤ zki i kompozycje jako agonisty receptora toll-like 7 |
| HRP20210927T1 (hr) | 2014-08-15 | 2021-09-03 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Spojevi pirolopirimidina koje se koriste kao agonist tlr7 |
| CN105732635A (zh) * | 2014-12-29 | 2016-07-06 | ๅไบฌๆๅพทๆฐ่ฏ็ ๅ่กไปฝๆ้ๅ ฌๅธ | ไธ็ฑปTollๆ ทๅไฝ7ๆฟๅจๅ |
| EP3368092B9 (en) * | 2015-10-29 | 2020-07-29 | Novartis AG | Antibody conjugates comprising toll-like receptor agonist |
| CN107043377A (zh) | 2016-02-05 | 2017-08-15 | ๆญฃๅคงๅคฉๆด่ฏไธ้ๅข่กไปฝๆ้ๅ ฌๅธ | ไธ็งtlr7ๆฟๅจๅ็ไธๆฐไน้ ธ็ใๆถๅbๅๅ ถๅถๅคๆนๆณใ่ฏ็ฉ็ปๅ็ฉๅ็จ้ |
| CN107043380A (zh) * | 2016-02-05 | 2017-08-15 | ๆญฃๅคงๅคฉๆด่ฏไธ้ๅข่กไปฝๆ้ๅ ฌๅธ | ไธ็งtlr7ๆฟๅจๅ็้ฉฌๆฅ้ ธ็ใๅ ถๆถๅcใๆถๅdใๆถๅeใๅถๅคๆนๆณๅ็จ้ |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | ํ๋ฆฌ์์ ผ ๋ฐ์ด์ค์ฌ์ด์ธ์์ค ์ธ์ฝํฌ๋ ์ดํฐ๋ | Bํ ๊ฐ์ผ ๋ฐ์ด๋ฌ์ค ๊ฒ๋ ๋ด์ ์ธ์ ์์ด์ ๋ํด ํน์ด์ ์ธ ์กฐ์๋ ๋ฉ๊ฐ๋ดํด๋ ์์ |
| AR111651A1 (es) * | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinaciรณn |
| US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
| US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
| US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
| US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
| US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
| ES2951817T3 (es) | 2017-08-22 | 2023-10-25 | Dynavax Tech Corp | Derivados de imidazoquinolina de cadena alquรญlica modificada como agonistas de TLR7/8 y usos de los mismos |
| WO2019066571A2 (ko) | 2017-09-28 | 2019-04-04 | ์ฐ์ธ๋ํ๊ต ์ฐํํ๋ ฅ๋จ | ๊ณจ์์ ๋ ๋ฉด์ญ๋ฐ์ ์ต์ ์ธํฌ์ ์ ์กฐ๋ฐฉ๋ฒ, ์ด์ ์ํด ์ ์กฐ๋ ๊ณจ์์ ๋ ๋ฉด์ญ๋ฐ์ ์ต์ ์ธํฌ ๋ฐ ๊ทธ ์ฉ๋ |
| US10722591B2 (en) | 2017-11-14 | 2020-07-28 | Dynavax Technologies Corporation | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ใฎใชใขใผใ ใตใคใจใณใทใผใบ๏ผ ใคใณใณใผใใฌใคใใใ | ๏ผจ๏ฝ๏ฝ่ค่ฃฝ้ปๅฎณๅคใจใใฆใฎ็ฝฎๆใใญใชใธใณๅๅ็ฉ |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | ๆทๅ ็งๅญธ้ขๆๆฉๅๅญธ่็็ฉๅๅญธ็ ็ฉถๆ | 2'3'-็ฐไบๆ ธ่ท้ ธ |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | ๆทๅ ็งๅญธ้ขๆๆฉๅๅญธ่็็ฉๅๅญธ็ ็ฉถๆ | ๏ผ๏ผ๏ผ๏ผโ็ฐไบๆ ธ่ท้ ธ |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | ๆทๅ ็งๅญธ้ขๆๆฉๅๅญธ่็็ฉๅๅญธ็ ็ฉถๆ | 3'3'-็ฐไบๆ ธ่ท้ ธ |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US20230053449A1 (en) * | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| WO2020154375A1 (en) * | 2019-01-22 | 2020-07-30 | Tufts Medical Center, Inc. | Methods and compositions for the treatment and prevention of ocular diseases and conditions |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | ็พๅๅบๅฉ็งๅญธ่กไปฝๆ้ๅ ฌๅธ | ้ก้ธๅ้ซ่ชฟ็ฏๅไนๅบ้ซๅฝขๅผ |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | ็พๅๅบๅฉ็งๅญธ่กไปฝๆ้ๅ ฌๅธ | ้ก้ธๅ้ซ่ชฟ็ฏๅไนๅบ้ซๅฝขๅผ |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| JP7590354B2 (ja) * | 2019-06-10 | 2024-11-26 | ในใใญ ใใคใชใใกใผใ ใคใณใณใผใใฌใผใใใ | ๅ ็ซ่ชฟ็ฏ็ฉ่ณชๆไฝ่ฌ็ฉใณใณใธใฅใฒใผใใใใณใใฎไฝฟ็จ |
| JP7706210B2 (ja) * | 2019-06-10 | 2025-07-11 | ในใใญ ใใคใชใใกใผใ ใคใณใณใผใใฌใผใใใ | ๏ผ๏ผจ๏ผใใญใญ๏ผป๏ผ๏ผ๏ผ๏ผ๏ฝ๏ผฝใใชใใธใณ๏ผ๏ผ๏ผ๏ผ๏ผใธใขใใๅๅ็ฉใใใณใใฎๆไฝใณใณใธใฅใฒใผใ |
| WO2021034804A1 (en) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| DK4037708T3 (da) | 2019-09-30 | 2024-09-30 | Gilead Sciences Inc | HBV-vacciner og fremgangsmรฅder til at behandle HBV |
| DK4069729T3 (da) | 2019-12-06 | 2025-04-07 | Prec Biosciences Inc | Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet |
| EP4097100A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| EP4097105A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| CN115135655B (zh) | 2020-01-27 | 2024-07-02 | ็พๆถ็พๆฝ่ดตๅฎๅ ฌๅธ | ไฝไธบTollๆ ทๅไฝ7(TLR7)ๆฟๅจๅ็1H-ๅกๅๅนถ[4,3-d]ๅงๅถๅๅ็ฉ |
| WO2021154661A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| WO2021154662A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| WO2021154667A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097104A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| KR20220132601A (ko) | 2020-01-27 | 2022-09-30 | ๋ธ๋ฆฌ์คํจ-๋ง์ด์ด์ค ์คํ ์ปดํผ๋ | ํจ-์ ์ฌ ์์ฉ์ฒด 7 (TLR7) ํจ๋ฅ์ ๋ก์์ 1H-ํผ๋ผ์กธ๋ก[4,3-d]ํผ๋ฆฌ๋ฏธ๋ ํํฉ๋ฌผ |
| CN115279765B (zh) | 2020-01-27 | 2024-11-12 | ็พๆถ็พๆฝ่ดตๅฎๅ ฌๅธ | ไฝไธบTollๆ ทๅไฝ7(TLR7)ๆฟๅจๅ็1H-ๅกๅๅนถ[4,3-d]ๅงๅถๅๅ็ฉ |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| WO2022241134A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ใฎใชใขใผใ ใตใคใจใณใทใผใบ๏ผ ใคใณใณใผใใฌใคใใใ | ใธใขใทใซใฐใชใปใญใผใซใญใใผใผ่ชฟ็ฏๅๅ็ฉ |
| AU2022299051B2 (en) | 2021-06-23 | 2025-03-13 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ใฎใชใขใผใ ใตใคใจใณใทใผใบ๏ผ ใคใณใณใผใใฌใคใใใ | ใธใขใทใซใฐใชใปใญใผใซใญใใผใผ่ชฟ็ฏๅๅ็ฉ |
| CN113476600B (zh) * | 2021-07-09 | 2023-05-30 | ๆตทๅๅคงๅญฆ | Avc-29ไฝไธบ็ซ่ไฝๅ็็จ้ไปฅๅๅซๆ่ฏฅไฝๅ็็ซ่็ปๅ็ฉ |
| AU2023373601A1 (en) | 2022-10-31 | 2025-04-03 | Astellas Pharma Inc. | Antibody-drug conjugate containing a toll-like receptor 7/8 dual agonist compound |
| WO2024118785A2 (en) | 2022-11-30 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69216509T2 (de) | 1991-08-12 | 1997-05-28 | Takeda Chemical Industries Ltd | Kondensierte Pyrimidinderivate, ihre Herstellung und ihre Verwendung als Antitumormittel |
| US5834469A (en) | 1994-06-09 | 1998-11-10 | Smithkline Beecham Corporation | Endothelin receptor antagonists |
| ES2321055T3 (es) | 1999-05-05 | 2009-06-02 | Aventis Pharma Limited | Compuestos biblicos sustituidos. |
| CN1918158B (zh) * | 2004-02-14 | 2011-03-02 | Irm่ดฃไปปๆ้ๅ ฌๅธ | ไฝไธบ่็ฝๆฟ้ ถๆๅถๅ็ๅๅ็ฉๅ็ปๅ็ฉ |
| WO2005092892A1 (ja) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | ๏ผโใชใญใฝใขใใใณๅๅ็ฉ |
| WO2005107760A1 (en) * | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| CA2569016C (en) | 2004-06-02 | 2012-11-27 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| ZA200610669B (en) * | 2004-06-02 | 2008-06-25 | Takeda Pharmaceutical | Fused heterocyclic compound |
| US20080188483A1 (en) * | 2005-03-15 | 2008-08-07 | Irm Llc | Compounds and Compositions as Protein Kinase Inhibitors |
| US20090105212A1 (en) | 2005-09-22 | 2009-04-23 | Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan | Novel adenine compound |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| CA2691444C (en) | 2007-06-29 | 2016-06-14 | Gilead Sciences, Inc. | Purine derivatives and their use as modulators of toll-like receptor 7 |
| PE20091485A1 (es) | 2008-02-06 | 2009-10-26 | Novartis Ag | DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS |
| TW201016703A (en) * | 2008-09-26 | 2010-05-01 | Takeda Pharmaceutical | Prevention and treatment of cancer with LKB1 non-expression (deletion or mutation) |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| KR20110117705A (ko) * | 2009-02-11 | 2011-10-27 | ๋ ๋ฆฌ์ ํธ ์ค๋ธ ๋ ์ ๋๋ฒ์ํฐ ์ค๋ธ ์บ๋ฆฌํฌ๋์ | ํจ-์ ์ฌ ์์ฉ์ฒด ์กฐ์ ์ ๋ฐ ์ง๋ณ์ ์น๋ฃ |
| WO2010117936A1 (en) | 2009-04-06 | 2010-10-14 | Schering Corporation | Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent |
| WO2011140338A1 (en) | 2010-05-05 | 2011-11-10 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| MX342164B (es) * | 2010-06-23 | 2016-09-19 | Hanmi Science Co Ltd | Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa. |
| WO2012066336A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| EP2570125A1 (en) | 2011-09-16 | 2013-03-20 | Almirall, S.A. | Ep1 receptor ligands |
| US8697888B2 (en) | 2012-01-06 | 2014-04-15 | Vanderbilt University | Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine M1 receptors |
| DK2906563T3 (en) | 2012-10-10 | 2018-06-06 | Janssen Sciences Ireland Uc | PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES |
| PL3137470T3 (pl) * | 2014-05-01 | 2021-10-11 | Novartis Ag | Zwiฤ zki i kompozycje jako agonisty receptora toll-like 7 |
-
2015
- 2015-04-29 ES ES15724409T patent/ES2908150T3/es active Active
- 2015-04-29 EP EP15724409.6A patent/EP3137468B1/en active Active
- 2015-04-29 WO PCT/US2015/028285 patent/WO2015168279A1/en not_active Ceased
- 2015-04-29 BR BR112016025048A patent/BR112016025048A2/pt not_active IP Right Cessation
- 2015-04-29 MX MX2016014308A patent/MX380777B/es unknown
- 2015-04-29 NZ NZ724878A patent/NZ724878A/en not_active IP Right Cessation
- 2015-04-29 AU AU2015253225A patent/AU2015253225B2/en not_active Ceased
- 2015-04-29 US US15/307,510 patent/US9944649B2/en active Active
- 2015-04-29 JP JP2016565403A patent/JP6541689B2/ja not_active Expired - Fee Related
- 2015-04-29 EA EA201692201A patent/EA032487B1/ru not_active IP Right Cessation
- 2015-04-29 CA CA2945504A patent/CA2945504A1/en not_active Abandoned
- 2015-04-29 SG SG11201608299TA patent/SG11201608299TA/en unknown
- 2015-04-29 CN CN201580021681.2A patent/CN106459058B/zh not_active Expired - Fee Related
- 2015-04-29 KR KR1020167030102A patent/KR20160144399A/ko not_active Ceased
-
2016
- 2016-10-11 IL IL248311A patent/IL248311B/en active IP Right Grant
-
2018
- 2018-02-27 US US15/906,424 patent/US10407431B2/en active Active
-
2019
- 2019-07-24 US US16/521,211 patent/US10844068B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170044168A1 (en) | 2017-02-16 |
| BR112016025048A2 (pt) | 2017-10-31 |
| EA032487B1 (ru) | 2019-06-28 |
| ES2908150T3 (es) | 2022-04-27 |
| IL248311B (en) | 2019-08-29 |
| AU2015253225B2 (en) | 2017-04-06 |
| EA201692201A1 (ru) | 2017-08-31 |
| JP2017514839A (ja) | 2017-06-08 |
| US10844068B2 (en) | 2020-11-24 |
| CN106459058B (zh) | 2019-07-05 |
| CN106459058A (zh) | 2017-02-22 |
| US9944649B2 (en) | 2018-04-17 |
| NZ724878A (en) | 2019-03-29 |
| US20180186802A1 (en) | 2018-07-05 |
| EP3137468A1 (en) | 2017-03-08 |
| IL248311A0 (en) | 2016-11-30 |
| MX2016014308A (es) | 2017-01-27 |
| WO2015168279A1 (en) | 2015-11-05 |
| US10407431B2 (en) | 2019-09-10 |
| AU2015253225A1 (en) | 2016-10-27 |
| MX380777B (es) | 2025-03-12 |
| EP3137468B1 (en) | 2021-10-06 |
| JP6541689B2 (ja) | 2019-07-10 |
| US20190345166A1 (en) | 2019-11-14 |
| KR20160144399A (ko) | 2016-12-16 |
| CA2945504A1 (en) | 2015-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL248347A0 (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
| IL248311A0 (en) | Compounds and preparations as agonists of toll-like receptor 7 | |
| GB201410905D0 (en) | Composition | |
| GB201404178D0 (en) | Composition | |
| GB201419437D0 (en) | Grease compositions | |
| GB201403017D0 (en) | Composition | |
| GB201408167D0 (en) | Compositions | |
| GB201406542D0 (en) | Intumescent compositions | |
| IL251479A0 (en) | components | |
| GB201414910D0 (en) | Composition | |
| GB201403561D0 (en) | Composition | |
| GB201419439D0 (en) | Grease compositions | |
| GB201420306D0 (en) | Compositions | |
| SG11201610547WA (en) | Solid composition | |
| GB201414555D0 (en) | Composition | |
| GB201410493D0 (en) | Composition | |
| GB201404700D0 (en) | Novel Composition | |
| HRP20190097T1 (hr) | Moluskicidni pripravak | |
| GB201404390D0 (en) | Composition | |
| GB201419435D0 (en) | Grease compositions | |
| GB201415483D0 (en) | Composition | |
| GB201403550D0 (en) | Composition | |
| GB201402648D0 (en) | Composition | |
| HK1230173A1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| GB201500985D0 (en) | Grease compositions |